Table 3.
Risk Factors for ≥2 Lines Improvement of Macular Edema-Induced Reduction of Visual Acuity
| Estimated Proportion Resolved (95% Confidence Interval) | Unadjusted | Adjusted** | |||||
|---|---|---|---|---|---|---|---|
| N | 6-Month | Hazard Ratio | p-value | Hazard Ratio | p-value | ||
| All | All | 1510 | 51.9% (49.0% - 54.6%) | n/a | |||
| Smoking | Never | 759 | 54.2% (50.3% - 57.8%) | 1.00 | 0.02 | 1.00 | 0.75 |
| Past | 188 | 50.3% (44.2% - 55.8%) | 0.90 (0.74 - 1.08) | 1.02 (0.84 - 1.24) | |||
| Current | 382 | 52.7% (47.7% - 57.2%) | 0.96 (0.83 - 1.11) | 0.97 (0.83 - 1.13) | |||
| Unknown | 181 | 42.7% (35.9% - 48.8%) | 0.71 (0.58 - 0.87) | 0.88 (0.70 - 1.10) | |||
| Visual Acuity at Diagnosis of ME | Better than 20/200 | 1122 | 48.9% (45.8% - 51.8%) | 1.00 | <0.001 | 1.00 | <0.001 |
| 20/200 or worse | 388 | 60.9% (55.6% - 65.6%) | 1.40 (1.22 - 1.60) | 1.46 (1.26 - 1.68) | |||
| Site of Uveitis | Anterior | 424 | 60.7% (55.6% - 65.2%) | 1.00 | <0.001 | 1.00 | 0.02 |
| Intermediate | 533 | 50.4% (46.3% - 54.2%) | 0.75 (0.65 - 0.87) | 0.83 (0.70 - 1.00) | |||
| Posterior | 285 | 49.6% (43.6% - 55.0%) | 0.74 (0.61 - 0.88) | 0.76 (0.63 - 0.93) | |||
| Panuveitis | 268 | 44.0% (38.4% - 49.2%) | 0.62 (0.51 - 0.75) | 0.73 (0.59 - 0.89) | |||
| Overall Activity at ME Diagnosis | Inactive | 436 | 46.5% (41.9% - 50.6%) | 1.00 | <0.001 | 1.00 | <0.01 |
| Slightly active | 211 | 41.0% (35.2% - 46.4%) | 0.85 (0.68 - 1.04) | 0.89 (0.70 - 1.13) | |||
| Active | 863 | 57.6% (54.0% - 60.9%) | 1.37 (1.20 - 1.58) | 1.27 (1.08 - 1.50) | |||
| Change in Anterior Chamber Cells | ≥2 steps better (or to 0) | * | 65.2% (60.5% - 69.3%) | 1.59 (1.39 - 1.83) | <0.001 <0.001† |
1.50 (1.29 - 1.74) | <0.001 <0.001† |
| 1 step better | * | 59.4% (49.9% - 67.1%) | 1.36 (1.06 - 1.72) | 1.31 (1.00 - 1.68) | |||
| No change | * | 48.5% (44.9% - 51.8%) | 1.00 | 1.00 | |||
| 1 step worse | * | 38.5% (30.9% - 45.3%) | 0.73 (0.57 - 0.93) | 0.77 (0.60 - 0.97) | |||
| ≥2 steps worse (or to 4+) | * | 35.0% (25.3% - 43.5%) | 0.65 (0.46 - 0.89) | 0.64 (0.45 - 0.87) | |||
| HLA-B27 | No | 1419 | 51.4% (48.5% - 54.1%) | 1.00 | 0.12 | 1.00 | 0.51 |
| Yes | 91 | 60.2% (47.1% - 70.1%) | 1.28 (0.99 - 1.62) | 1.10 (0.85 - 1.42) | |||
| Cataract Surgery prior to ME | No | 1114 | 53.3% (50.1% - 56.3%) | 1.00 | 0.08 | 1.00 | 0.07 |
| Aphakic | 135 | 44.2% (36.1% - 51.4%) | 0.77 (0.61 - 0.96) | 0.75 (0.58 - 0.95) | |||
| Pseudophakic | 261 | 49.9% (44.3% - 55.0%) | 0.91 (0.77 - 1.07) | 0.88 (0.74 - 1.05) | |||
| Hypotony (<5 mmHg) | No | * | 52.2% (49.3% - 54.9%) | 1.00 | <0.01 | 1.00 | <0.01 |
| Yes | * | 14.6% (0.0% - 27.3%) | 0.21 (0.07 - 0.50) | 0.21 (0.06 - 0.49) | |||
| Ocular hypertension (>21 mmHg) | No | * | 51.2% (48.2% - 54.0%) | 1.00 | 0.11 | 1.00 | 0.32 |
| Yes | * | 57.3% (49.3% - 64.0%) | 1.19 (0.97 - 1.44) | 1.11 (0.90 - 1.36) | |||
*
Time updated covariates vary in their number at risk over time, and therefore cannot be represented by a single number.
**
Adjusted for all other variables in the table.
†
Test of linear trend across categories.
Abbreviation: ME = macular edema.